NanoVation Therapeutics
  • Team
  • Technology
  • Partnership
  • News & Events
  • Careers
Select Page
Durable gene expression for treating genetic diseases

Durable gene expression for treating genetic diseases

by NanoVation | Mar 30, 2023 | Liver, Tissue

Adminstration route: i.v. Platform technology: HepLNP Modality: DNA Indication: not disclosed Strategy:...
Durable gene expression for treating genetic diseases

Gene editing in hepatocytes for genetic disease

by NanoVation | Mar 30, 2023 | Liver, Tissue

Adminstration route: i.v. Platform technology: HepLNP Modality: mRNA/gRNA Indication: not disclosed Strategy:...
Durable gene expression for treating genetic diseases

Gene silencing in hepatocytes for genetic disease

by NanoVation | Mar 29, 2023 | Liver, Tissue

Adminstration route: i.v. Platform technology: HepLNP Modality: siRNA Indication: not disclosed Strategy:...

Recent Posts

  • NanoVation’s ligand-free lcLNP™ achieves complete B cell depletion in NHP at 0.1 mg/kg
  • NanoVation wins “Deal of the Year” award from Life Sciences BC
  • NanoVation featured on Biotech TV
  • NanoVation announces expansion of Board of Directors & completion of funding round led by Convergent Ventures
  • VIDEO: NanoVation CEO Dom Witzigmann at CLINAM 2023

Recent Comments

No comments to show.
  • Publications
  • Contact

  • Legal < Privacy Policy

  • Careers
    • Openings
  • News & Events

  • Technology
    • Toolbox
    • Preclinical Data
  • Partnership

    • Pipeline
  • Home

  • Team
    • Qualifications
    • Profiles
linkedin logo
YouTube logo
© NanoVation 2025